CGTX vs DBVT vs ALKS vs SAVA vs ACAD

For growth investors, ACADIA Pharmaceuticals Inc.

(ACAD) is the stronger pick with 11. 9% revenue growth year-over-year, versus -5. 2% for Alkermes plc (ALKS). ACADIA Pharmaceuticals Inc. (ACAD) offers the better valuation at 9. 8x trailing P/E (55. 6x forward), making it the more compelling value choice. Analysts rate Cognition Therapeutics, Inc. (CGTX) a "Buy" — based on 7 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, ACADIA Pharmaceuticals Inc.

(ACAD) is the cheapest at 9. 8x versus Alkermes plc at 24. 5x.

Over the past 5 years, Alkermes plc (ALKS) delivered a total return of +61.

7%, compared to -90. 5% for Cognition Therapeutics, Inc. (CGTX). Over 10 years, the gap is even starker: ALKS returned -12. 0% versus CGTX's -90. 5%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Alkermes plc (ALKS) is the lower-risk stock at 1.

00β versus Cognition Therapeutics, Inc. 's 3. 44β — meaning CGTX is approximately 245% more volatile than ALKS relative to the S&P 500. On balance sheet safety, Cognition Therapeutics, Inc. (CGTX) carries a lower debt/equity ratio of 2% versus 13% for DBV Technologies S. A. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), ACADIA Pharmaceuticals Inc.

(ACAD) is pulling ahead at 11. 9% versus -5. 2% for Alkermes plc (ALKS). On earnings-per-share growth, the picture is similar: Cassava Sciences, Inc. grew EPS 77. 6% year-over-year, compared to -347. 5% for DBV Technologies S. A.. Over a 3-year CAGR, ACAD leads at 27. 5% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

ACADIA Pharmaceuticals Inc.

(ACAD) is the more profitable company, earning 36. 5% net margin versus 0. 0% for Cassava Sciences, Inc. — meaning it keeps 36. 5% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ALKS leads at 17. 2% versus 0. 0% for SAVA. At the gross margin level — before operating expenses — ACAD leads at 91. 7%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

Analyst consensus price targets imply the most upside for DBVT: 134.

8% to $46. 33.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Alkermes plc (ALKS) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1.

00)). Cognition Therapeutics, Inc. (CGTX) carries a higher beta of 3. 44 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (ALKS: -12. 0%, CGTX: -90. 5%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: CGTX is a small-cap quality compounder stock; DBVT is a mega-cap quality compounder stock; ALKS is a small-cap quality compounder stock; SAVA is a small-cap quality compounder stock; ACAD is a small-cap deep-value stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.